Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00314808 · ClinicalTrials.gov registry record · Phase 1

A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas

A Phase 1 study, sponsored by Duke University.

Completed
Registry status
Phase 1
Development phase
33
Enrollment target

NCT00314808 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 33 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00314808, a Phase 1 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 1
Development phase
33 participants
Enrollment target

Study Summary

This study seeks to define the tolerability and safety associated with the administration of Dronabinol in the treatment of adults with nausea, vomiting and appetite loss in patients with primary gliomas who are undergoing chemotherapy treatment. The study will also describe the effect of Dronabinol on the quality of life in terms of nausea, vomiting and anorexia in this patient group.

Interventions

  • DRUG Dronabinol

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2006-04
Est. Completion 2012-04
Phase Phase 1

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT00314808

The ClinicalTrials.gov registry entry for NCT00314808 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Dronabinol is the first listed.

NCT00314808 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00314808 about?

NCT00314808 is a clinical study titled "A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas". This study seeks to define the tolerability and safety associated with the administration of Dronabinol in the treatment of adults with nausea, vomiting and appetite loss in patients with primary gliomas who are undergoing chemotherapy treatment. The study will also describe the effect of Dronabinol...

What is the current status of trial NCT00314808?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2006-04. Estimated completion is 2012-04.

What interventions are being tested in trial NCT00314808?

The interventions under investigation include: Dronabinol (DRUG).

Who is sponsoring clinical trial NCT00314808?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.